# Semaglutide vs Tirzepatide vs Retatrutide 2026: Receptor Differences, Research Evidence & LOOT10
-
Semaglutide, tirzepatide, and retatrutide are often grouped together as the next generation of metabolic peptides, but they are not three versions of the same molecule. Semaglutide primarily targets the GLP-1 receptor, tirzepatide activates both GIP and GLP-1 receptors, and retatrutide is designed to activate GIP, GLP-1, and glucagon receptors. That progression—from single to dual to triple receptor activity—is the most useful starting point for understanding how the three differ.
For researchers comparing current research materials, the practical questions go beyond receptor count. Molecular structure, analytical characterization, clinical evidence, regulatory status, and batch documentation all matter. American Peptides currently lists research versions of all three compounds and provides lot-related documentation and quantity pricing. The current promotion supplied for this comparison is
LOOT10, advertised for up to 30% off through the American Peptides offer page; the actual applicable saving should be verified at checkout. (https://www.americanpeptides.us/loot30)This guide is designed to answer the questions that usually require several separate articles: How does semaglutide differ from tirzepatide? What does retatrutide add? Which receptor does each compound target? How mature is the evidence for each one in 2026? How should the molecules be compared analytically? And what should a researcher verify before selecting research material?
The three compounds in one table
Research dimension Semaglutide Tirzepatide Retatrutide Broad receptor architecture GLP-1R GIPR + GLP-1R GIPR + GLP-1R + GCGR Receptor count 1 2 3 Peptide length 31 aa 39 aa 39 aa Approx. molecular weight ~4.11 kDa ~4.81 kDa ~4.73 kDa Key structural idea Lipidated GLP-1 analogue Lipidated dual agonist Lipidated triple agonist Clinical evidence maturity Extensive Extensive Rapidly expanding, still investigational U.S. pharmaceutical status Approved semaglutide products Approved tirzepatide products Investigational Research-material question GLP-1 reference model Dual GIP/GLP-1 model Triple GIP/GLP-1/glucagon model The molecular distinctions are well established in current chemical and research references. PubChem lists semaglutide as a GLP-1 receptor agonist, tirzepatide as a dual GIP/GLP-1 agonist, and retatrutide as a multi-receptor investigational molecule.
The simplest way to understand the progression
Think of the three compounds as three different receptor architectures:
Semaglutide
GLP-1
↓
Tirzepatide
GIP + GLP-1
↓
Retatrutide
GIP + GLP-1 + glucagon
That sequence does not mean “one receptor, then two, then three, therefore automatically better.”
It means the molecular hypothesis changes.
Semaglutide asks what can be achieved by sustained GLP-1 receptor activation.
Tirzepatide asks what happens when GIP and GLP-1 receptor signaling are brought together.
Retatrutide asks what happens when glucagon-receptor activity is added to that dual incretin framework.
That is the more scientifically useful interpretation.
Why receptor architecture matters
The three receptors are related through broader metabolic biology, but they are distinct pharmacological targets.
GLP-1 receptor
GLP-1R is a class B G-protein-coupled receptor associated with incretin signaling.
It is heavily studied in:
- pancreatic islet biology,
- glucose-dependent insulin signaling,
- gastrointestinal physiology,
- neural signaling,
- and metabolic regulation.
Semaglutide provides a well-characterized tool for studying this pathway.
GIP receptor
GIPR is another incretin receptor.
Its biology is related to GLP-1R but not identical.
Tirzepatide incorporates GIPR activity alongside GLP-1R, while retatrutide goes one step further by adding GCGR activity.
Glucagon receptor
GCGR is associated with glucagon signaling and broader metabolic regulation, including pathways related to hepatic glucose handling and substrate metabolism.
Retatrutide's inclusion of GCGR is its defining difference from tirzepatide.
Semaglutide: the GLP-1 reference point
Semaglutide is a 31-amino-acid engineered analogue of GLP-1.
Its molecular structure is designed to improve resistance to enzymatic degradation and extend circulating exposure. PubChem lists semaglutide under CAS 910463-68-2 and describes it as a lipopeptide and GLP-1 receptor agonist.
The molecule includes a lipid-containing side chain that promotes reversible albumin binding.
That matters because the duration of action of a peptide depends on more than receptor affinity.
It depends on:
- enzymatic stability,
- protein binding,
- distribution,
- renal clearance,
- and molecular design.
Semaglutide therefore remains an important reference model for long-acting GLP-1 pharmacology.
For a full semaglutide-specific discussion, the related research guide in this content cluster is:
Tirzepatide: adding GIP to GLP-1
Tirzepatide is a 39-amino-acid synthetic peptide designed as a dual GIP/GLP-1 receptor agonist.
PubChem lists the molecule as C225H348N48O68 with a molecular weight of approximately 4,813 g/mol and describes its C20 fatty-diacid conjugation.
The important conceptual difference is simple:
Semaglutide = GLP-1
Tirzepatide = GIP + GLP-1
That makes tirzepatide particularly useful for studying the effect of dual incretin receptor activity.
The molecule also has a long-acting design, with its lipid modification contributing to prolonged pharmacokinetic behavior.
For a complete tirzepatide-specific treatment, see:
Retatrutide: adding glucagon to the dual architecture
Retatrutide, or LY3437943, extends the architecture further:
GIP + GLP-1 + glucagon
It is a 39-amino-acid synthetic peptide engineered as a triple hormone-receptor agonist. Current clinical-development reporting continues to identify retatrutide as investigational.
That means the comparison is not:
“semaglutide vs a stronger semaglutide.”
It is:
GLP-1-only vs GIP/GLP-1 dual signaling vs GIP/GLP-1/glucagon triple signaling.
That is a much more useful way to think about the three.
For the complete retatrutide research guide:
https://peptidesresearchguide.blogspot.com/2026/08/retatrutide-research-guide-2026.html
Molecular structure comparison
The receptor profile gets most of the attention, but the chemistry matters just as much.
Structural feature Semaglutide Tirzepatide Retatrutide Peptide length 31 aa 39 aa 39 aa Lipidated Yes Yes Yes Long-acting design Yes Yes Yes Core research identity GLP-1 analogue GIP/GLP-1 dual agonist GIP/GLP-1/glucagon triple agonist Structural modifications Extensive Extensive Extensive Semaglutide, tirzepatide, and retatrutide are therefore all engineered peptides rather than simple copies of their endogenous hormones.
The differences in sequence, substitutions, linker architecture, and lipid side chains influence:
- receptor engagement,
- enzymatic stability,
- protein binding,
- pharmacokinetics,
- and assay behavior.
Why peptide length alone is not enough
At first glance, semaglutide is 31 amino acids while tirzepatide and retatrutide are 39.
That may sound like a small difference.
It isn't necessarily.
A peptide's behavior depends on:
sequence + modifications + conformation + lipidation + receptor interactions
rather than amino-acid count alone.
Two peptides with the same number of residues can behave very differently if their sequences and modifications are different.
That is why a serious molecular comparison needs to go beyond peptide length.
A useful research comparison: receptor activity vs clinical outcome
This is where many online comparison pages become misleading.
There are two different questions:
Question 1 — What does the molecule do at the receptor level?
That can be studied through:
- receptor-binding assays,
- cAMP assays,
- cellular signaling,
- receptor internalization,
- structural biology,
- and pharmacological profiling.
Question 2 — What happens in humans?
That requires:
- randomized clinical trials,
- defined pharmaceutical formulations,
- specific doses and schedules,
- controlled populations,
- and safety monitoring.
Those two evidence levels should not be mixed.
A molecule can have an interesting receptor profile without having a mature clinical evidence base.
And a clinical effect does not automatically tell you every detail of the underlying receptor mechanism.
Semaglutide's clinical evidence
Semaglutide has the most mature evidence base of these three molecules.
In STEP 1, 1,961 adults with overweight or obesity without diabetes were randomized to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The published trial reported a mean body-weight change of −14.9% with semaglutide versus −2.4% with placebo.
That trial is important for another reason.
It illustrates the distinction between:
clinical evidence about an approved pharmaceutical formulation
and
analytical evidence about research material.
The first involves a controlled intervention in humans.
The second concerns a laboratory material's identity and composition.
They answer different questions.
Tirzepatide's clinical evidence
Tirzepatide also has a substantial clinical literature.
In SURPASS-2, tirzepatide was compared directly with once-weekly semaglutide in adults with type 2 diabetes.
The trial found greater reductions in HbA1c and body weight with tirzepatide across the studied dose groups. The most common adverse events were gastrointestinal.
Later, SURMOUNT-5 provided a direct comparison in adults with obesity but without type 2 diabetes.
The Phase 3b trial randomized participants to maximum tolerated tirzepatide or semaglutide for 72 weeks and concluded that tirzepatide was superior to semaglutide for reduction in body weight and waist circumference.
This is a particularly useful comparison because it comes from a direct head-to-head trial, not from two unrelated studies.
Why direct trials matter
Suppose Study A reports a large effect for Drug A.
Study B reports a somewhat smaller effect for Drug B.
It is tempting to conclude:
A > B
But that comparison can be misleading because:
- populations differ,
- follow-up duration differs,
- background treatment differs,
- endpoints differ,
- statistical methods differ,
- and dropout patterns can differ.
A direct randomized comparison solves much of that problem.
That is why SURMOUNT-5 is more informative for a semaglutide-vs-tirzepatide question than comparing two separate placebo-controlled trials.
Retatrutide's clinical evidence is newer
Retatrutide has a substantial and rapidly expanding clinical programme, but it remains investigational.
The original Phase 2 obesity trial provided evidence that the molecule could produce substantial dose-dependent changes in body weight.
Since then, the programme has advanced into Phase 3.
In May 2026, Lilly reported that participants receiving 12 mg retatrutide in TRIUMPH-1 lost an average of 28.3% of body weight at 80 weeks in the trial population.
In July 2026, Lilly reported results from TRIUMPH-2 and TRIUMPH-3, including average weight losses of up to 20.8% and 22.6%, respectively, depending on the population and trial. Lilly said it planned to submit a BLA to the FDA in Q1 2027.
These are important developments, but they do not make retatrutide an approved drug.
As of August 2026, it remains investigational.
Why retatrutide cannot simply be “ranked” against the other two
This is a subtle point.
Semaglutide and tirzepatide have substantial approved-product experience.
Retatrutide has an increasingly mature clinical-development programme but remains pre-approval.
So a comparison like:
“Which is best?”
can accidentally mix three different things:
- receptor architecture,
- clinical evidence maturity,
- and regulatory status.
A more useful comparison is:
What question does each molecule answer?
What each compound is best understood as a research model
Semaglutide
Best understood as a long-acting GLP-1 receptor model.
Tirzepatide
Best understood as a dual GIP/GLP-1 receptor model.
Retatrutide
Best understood as a triple GIP/GLP-1/glucagon receptor model.
That framing is more precise than calling one “stronger” without specifying what “stronger” means.
How the clinical evidence should be compared
A useful evidence matrix looks like this:
Evidence dimension Semaglutide Tirzepatide Retatrutide Receptor mechanism established Yes Yes Yes Large clinical programme Yes Yes Yes Head-to-head with another in this trio Yes, via direct comparisons Yes No direct three-way trial U.S. approved pharmaceutical products Yes Yes No Current status Mature/approved Mature/approved Investigational Phase 3 program in 2026 — Ongoing/expanded indications Active and rapidly expanding The most important caveat is the last comparison.
There is no randomized three-way clinical trial directly comparing semaglutide, tirzepatide, and retatrutide under one protocol.
That means there is no scientifically clean basis for saying that one produces a particular percentage “better” than both other compounds from separate trials.
Why network meta-analysis needs caution
Network meta-analyses can provide valuable indirect comparisons across clinical trials.
They are useful when direct head-to-head trials are unavailable.
But indirect comparisons rely on assumptions about transitivity and comparable trial populations.
A recent network meta-analysis reported strong efficacy signals for tirzepatide and retatrutide relative to placebo across available randomized trials.
That is useful context.
It is not the same as putting all three molecules in one randomized trial.
For SEO content, this distinction is worth making explicit because it prevents a common overclaim:
Indirect evidence is not direct evidence.
The receptor-level comparison
A simplified receptor table is one of the most useful tools in this entire topic.
Receptor Semaglutide Tirzepatide Retatrutide GLP-1R ✓ ✓ ✓ GIPR — ✓ ✓ GCGR — Minimal/absent in the intended dual-agonist design ✓ The critical addition is glucagon receptor activity.
That is what distinguishes retatrutide from tirzepatide.
Semaglutide sits at the single-receptor end of the continuum.
Receptor count is not receptor equivalence
One trap in simplified comparison articles is treating a receptor count like a score.
It isn't.
Three receptors do not automatically mean:
three times the effect
And two receptors do not necessarily mean:
twice the effect
Each receptor has its own:
- affinity,
- expression pattern,
- signaling network,
- physiological role,
- and tissue context.
The chemistry of the ligand also matters.
That is why receptor architecture is more useful than receptor counting.
The molecular weight comparison
Approximate molecular weights are:
- Semaglutide: ~4.11 kDa
- Tirzepatide: ~4.81 kDa
- Retatrutide: ~4.73 kDa
PubChem currently lists approximately 4,114 g/mol for semaglutide and 4,813 g/mol for tirzepatide.
The difference in molecular weight reflects more than peptide length.
Lipidation and structural modifications contribute significantly to the overall molecular composition.
For analytical work, molecular weight therefore becomes a useful identity check, not merely a descriptive statistic.
How HPLC fits into the comparison
When buying or evaluating research material, HPLC is useful because it provides information about chromatographic purity.
A researcher comparing the three compounds should ask:
- Was HPLC performed?
- What method was used?
- What purity was reported?
- Was the sample lot-matched?
- Were related substances documented?
A product labeled “≥99% pure” without analytical context provides less information than an actual batch-level chromatogram or certificate.
How mass spectrometry fits into the comparison
Mass spectrometry approaches the problem from another direction.
The primary question is:
Does the measured molecular mass fit the expected molecule?
That can help support identity.
The distinction is straightforward:
HPLC → purity/composition information
Mass spectrometry → molecular identity/mass information
For a comparison of three closely studied peptide compounds, having both kinds of evidence is particularly useful.
Why a lot-matched COA matters
A generic certificate might say:
Semaglutide — ≥99%
A lot-matched certificate can say:
Semaglutide — Lot X — measured purity — measured mass — test date
The second is much more useful for traceability.
The same principle applies to tirzepatide and retatrutide.
For a laboratory project where repeatability matters, researchers should ideally record:
compound → lot → COA → storage history → experiment
That creates a better chain of experimental provenance.
Current American Peptides comparison
American Peptides currently lists all three compounds as research materials.
Based on the current product information:
Product Displayed starting price Example current formats Semaglutide $60 5, 10, 20, 30, 50 mg Tirzepatide $100 10, 20, 30, 60, 100 mg Retatrutide $105 10, 20, 30, 48, 60 mg The displayed prices can change, and some configurations may be temporarily unavailable.
The important analytical point is that price per milligram isn't automatically a meaningful scientific comparison.
These are different molecules with different molecular weights, different receptor profiles, and different research questions.
Why price-per-mg can be misleading
Imagine two compounds with the same nominal price per milligram.
That doesn't make them equivalent.
One might be:
- a single-receptor agonist,
- another a dual agonist,
- another a triple agonist.
The molecule is different.
The assay is different.
The research question is different.
So price should be interpreted within the context of the experiment, not as a universal quality score.
Where the LOOT10 promotion fits
For researchers who have already narrowed the choice to a specific compound and configuration, the supplied
LOOT10promotion is the commercial variable worth checking.The current offer is:
LOOT10 — up to 30% off
https://www.americanpeptides.us/loot30
American Peptides also displays quantity pricing and other promotional mechanisms on individual product pages, so the useful figure is the final price for the actual cart, not the maximum headline percentage.
That is especially important when comparing:
- one unit,
- several units,
- or larger research orders.
A better buying framework than “Which peptide is cheapest?”
Use this sequence:
1. Define the receptor question
Do you need GLP-1 only, GIP + GLP-1, or GIP + GLP-1 + glucagon?
2. Define the molecular question
What exact molecule and structure does the experiment require?
3. Define analytical requirements
Do you need:
- HPLC,
- mass spectrometry,
- lot matching,
- sterility,
- endotoxin,
- or other testing?
4. Define the required amount
Avoid comparing a 5 mg configuration against a 100 mg configuration as if they were the same purchase.
5. Review the batch documentation
Check the actual COA.
6. Then compare price
Apply the current promotion and compare against quantity pricing.
This is a much better purchasing framework for research material.
Which compound has the most mature evidence?
That depends on what “mature” means.
Clinical evidence breadth
Semaglutide has an exceptionally broad and mature body of clinical evidence.
Dual-receptor clinical evidence
Tirzepatide also has an extensive programme, including direct head-to-head comparisons with semaglutide.
Emerging multi-receptor clinical evidence
Retatrutide has moved rapidly into Phase 3 and produced major 2026 results, but it remains investigational.
So there is no contradiction in saying:
Retatrutide is highly advanced for an investigational molecule while semaglutide has the more mature overall evidence base.
Which compound has the simplest mechanism?
From a receptor-target perspective:
Semaglutide
It primarily addresses one receptor.
That simplicity can be valuable in experimental design.
Which has the most complex receptor architecture?
Retatrutide
It combines:
GIPR + GLP-1R + GCGR
That creates more mechanistic variables and therefore more interesting questions—but also a more complicated interpretation.
Which sits in the middle?
Tirzepatide
It combines:
GIPR + GLP-1R
That makes it a useful bridge between single-receptor and triple-receptor research architectures.
The role of cagrilintide in this comparison
Cagrilintide does not fit neatly into the same single/dual/triple incretin sequence.
It belongs to the amylin/calcitonin receptor family.
That makes it complementary rather than directly interchangeable with the three compounds above.
Its research guide is here:
https://juanparada1.substack.com/p/cagrilintide-research-guide-2026?r=8tof2y
This distinction is useful because the metabolic-peptide field is broader than GLP-1 receptor agonism alone.
Retatrutide + cagrilintide is a different question
The combined formulation of retatrutide and cagrilintide brings together:
GIP + GLP-1 + glucagon
and
amylin/calcitonin signaling
That is a different research question from comparing semaglutide, tirzepatide, and retatrutide.
The companion article in this cluster is:
Common mistakes when comparing these three
Mistake 1: Treating all three as interchangeable GLP-1s
They are not.
Mistake 2: Ranking them by receptor count
Receptor number is not an efficacy score.
Mistake 3: Comparing separate clinical trials as if they were head-to-head
Different trial designs produce different contexts.
Mistake 4: Treating retatrutide's 2026 Phase 3 results as FDA approval
It remains investigational. Lilly said in July 2026 that it planned an FDA BLA submission for Q1 2027.
Mistake 5: Treating research material as pharmaceutical-equivalent
The molecular name may match while formulation, manufacturing, labeling, and regulatory context differ.
Mistake 6: Looking only at purity
A purity number is not a complete analytical profile.
Mistake 7: Comparing price without comparing quantity
A $60 5 mg configuration and a $100 10 mg configuration answer different purchasing questions.
Frequently asked questions
What is the difference between semaglutide, tirzepatide, and retatrutide?
Semaglutide is primarily a GLP-1 receptor agonist, tirzepatide activates GIP and GLP-1 receptors, and retatrutide is designed to activate GIP, GLP-1, and glucagon receptors.
Is semaglutide a single agonist?
Yes. Semaglutide is principally a GLP-1 receptor agonist.
Is tirzepatide a dual agonist?
Yes. Tirzepatide is designed to activate GIP and GLP-1 receptors.
Is retatrutide a triple agonist?
Yes. Retatrutide is designed to activate GIP, GLP-1, and glucagon receptors.
Which is the most advanced clinically: semaglutide, tirzepatide, or retatrutide?
Semaglutide and tirzepatide have approved pharmaceutical products and extensive clinical evidence. Retatrutide has advanced into Phase 3 and produced major results in 2026 but remains investigational.
Is retatrutide FDA approved in 2026?
No. As of August 2026, retatrutide remains investigational. Lilly said in July 2026 that it plans to submit a BLA to the FDA in Q1 2027.
Has tirzepatide been directly compared with semaglutide?
Yes. SURMOUNT-5 directly compared maximum tolerated tirzepatide with maximum tolerated semaglutide in adults with obesity without diabetes and found tirzepatide superior for body-weight and waist-circumference reduction at 72 weeks.
Has semaglutide been directly compared with retatrutide?
There is no major randomized three-way clinical trial establishing a direct semaglutide-versus-retatrutide comparison under the same protocol. Their evidence bases largely come from separate development programmes.
Has tirzepatide been directly compared with retatrutide?
A direct randomized clinical comparison under one definitive head-to-head obesity protocol has not established a clean answer to that question.
Why can't you simply compare the largest weight-loss percentage from each trial?
Because different trials can have different participants, durations, endpoints, background interventions, estimands, and dropout patterns. Direct randomized comparisons are more informative than cross-trial headline comparisons.
What is the molecular weight of semaglutide?
PubChem lists a calculated molecular weight of approximately 4,114 g/mol for semaglutide.
What is the molecular weight of tirzepatide?
PubChem lists approximately 4,813 g/mol for tirzepatide.
What is the approximate molecular weight of retatrutide?
Retatrutide is approximately 4.73 kDa, based on its reported molecular architecture.
What does HPLC tell you when comparing research peptides?
HPLC provides chromatographic information that can be used to assess the purity profile of the tested material.
What does mass spectrometry tell you?
Mass spectrometry provides molecular-mass information that can support characterization of the compound's molecular identity.
Why is a lot-matched COA important?
It connects the analytical result to a specific batch, giving researchers better traceability than a generic certificate.
Are research versions of semaglutide, tirzepatide, and retatrutide the same as pharmaceutical products?
They should not be assumed to be equivalent. Approved pharmaceutical products exist within regulated manufacturing and quality frameworks that differ from research-use materials.
What is the current American Peptides price for semaglutide?
The displayed starting price is currently $60 for 5 mg, although price and availability can change.
What is the current American Peptides price for tirzepatide?
The displayed starting price is currently $100 for 10 mg, with quantity pricing shown on the product page.
What is the current American Peptides price for retatrutide?
The displayed starting price is currently $105 for 10 mg, with additional configurations and quantity pricing available.
Does American Peptides offer a discount code for these compounds?
The promotion supplied for this article is LOOT10, advertised for up to 30% off through the current offer.
How do I check the LOOT10 discount?
Visit:
https://www.americanpeptides.us/loot30
Apply LOOT10 where applicable and verify the final discount displayed in the cart.
Does LOOT10 guarantee 30% off every compound?
No. The promotion is described as up to 30% off, so the actual saving should be verified against the current offer and the specific cart.
The evidence-first verdict
If the goal is to understand the three compounds scientifically, the best way to summarize them is not “one is best.”
It is:
Semaglutide
The established GLP-1 reference model.
It offers the most mature overall evidence base and a comparatively focused receptor architecture.
Tirzepatide
The established dual GIP/GLP-1 model.
It adds GIP receptor activity and has extensive clinical evidence, including direct comparison with semaglutide.
Retatrutide
The emerging triple-receptor model.
It adds glucagon receptor activity to the GIP/GLP-1 framework and has moved rapidly into Phase 3, with significant 2026 results, while remaining investigational.
That gives the three compounds a logical research progression:
single receptor → dual receptors → triple receptors
But receptor count should never be mistaken for an automatic hierarchy.
The actual research question should determine which molecule is relevant.
Current promotional consideration
For readers who have completed the scientific comparison and are now evaluating current research-material pricing, the supplied American Peptides offer is:
Promo code:
LOOT10— up to 30% offOffer page:
https://www.americanpeptides.us/loot30Because the supplier also displays quantity-based pricing, compare the actual final checkout price for the specific compound and quantity rather than assuming the maximum promotional percentage applies uniformly.
That is the more defensible way to use a coupon within a research-focused article.
Research-cluster references
Retatrutide Research Guide 2026
https://peptidesresearchguide.blogspot.com/2026/08/retatrutide-research-guide-2026.html
Cagrilintide Research Guide 2026
https://juanparada1.substack.com/p/cagrilintide-research-guide-2026?r=8tof2y
Retatrutide + Cagrilintide Research Guide
Semaglutide Research Guide 2026
Tirzepatide Research Guide 2026
Supporting promotional/reference Gist
https://gist.github.com/waseemsahirofficial2-dev/2dc0806c9536dfd8893a0c60ccc91a41
The external supporting pages are useful for building a topical cluster around the individual compounds. The GitHub Gist is best treated as a promotional/reference resource rather than as a primary scientific source.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Register Login